Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.54 USD | +1.72% | +14.19% | -19.55% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 36.49 | 12.09 | 84.69 | 78.65 | - | - |
Enterprise Value (EV) 1 | 36.49 | 12.09 | 84.69 | 78.65 | 78.65 | 78.65 |
P/E ratio | - | -0.37 x | -2.3 x | -2.51 x | -2.22 x | -1.7 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | 7.34 x |
EV / Revenue | - | - | - | - | - | 7.34 x |
EV / EBITDA | -1.35 x | -0.35 x | -2.94 x | -2.22 x | -1.85 x | -1.55 x |
EV / FCF | - | - | -3.08 x | -2.51 x | -1.88 x | -1.23 x |
FCF Yield | - | - | -32.5% | -39.8% | -53.1% | -81% |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 6,910 | 10,517 | 19,247 | 22,217 | - | - |
Reference price 2 | 5.280 | 1.150 | 4.400 | 3.540 | 3.540 | 3.540 |
Announcement Date | 3/29/22 | 3/22/23 | 3/19/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 10.71 |
EBITDA 1 | - | -26.99 | -34.64 | -28.78 | -35.5 | -42.6 | -50.8 |
EBIT 1 | - | -26.99 | -34.64 | -29.16 | -33.18 | -43.04 | -58.97 |
Operating Margin | - | - | - | - | - | - | -550.47% |
Earnings before Tax (EBT) 1 | - | - | -35.71 | -29.49 | -33.23 | -42.96 | -58.38 |
Net income 1 | -19.21 | - | -35.71 | -29.49 | -33.23 | -42.96 | -58.38 |
Net margin | - | - | - | - | - | - | -545.04% |
EPS 2 | - | - | -3.090 | -1.910 | -1.412 | -1.593 | -2.084 |
Free Cash Flow 1 | - | - | - | -27.53 | -31.3 | -41.8 | -63.7 |
FCF margin | - | - | - | - | - | - | -594.66% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 4/13/21 | 3/29/22 | 3/22/23 | 3/19/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | -7.736 | -7.338 | - | -8.662 | -8.771 | -8.934 | -7.581 | -7.387 | -6.504 | -7.429 | -7.8 | -8.3 | -8.7 | -10.9 | - |
EBIT 1 | -7.736 | -7.338 | -8.161 | -8.774 | -8.771 | -8.934 | -7.581 | -7.47 | -6.592 | -7.514 | -7.609 | -7.981 | -8.11 | -8.998 | -9.5 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | - | - | - | - | -9.103 | -7.636 | -7.581 | -6.786 | -7.488 | -7.612 | -8.068 | -8.173 | -9.203 | -9.9 |
Net income 1 | - | - | - | - | - | -9.103 | -7.636 | -7.581 | -6.786 | -7.488 | -7.612 | -8.068 | -8.173 | -9.203 | -9.9 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | - | - | - | - | - | -0.6300 | -0.5500 | -0.5400 | -0.4800 | -0.3400 | -0.3740 | -0.3600 | -0.3240 | -0.3560 | -0.4850 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/10/21 | 3/29/22 | 5/13/22 | 8/15/22 | 11/8/22 | 3/22/23 | 5/10/23 | 8/10/23 | 11/8/23 | 3/19/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | -27.5 | -31.3 | -41.8 | -63.7 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | - | 0.17 | 0.2 | 0.65 | 0.9 |
Capex / Sales | - | - | - | - | - | - | 8.41% |
Announcement Date | 4/13/21 | 3/29/22 | 3/22/23 | 3/19/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.55% | 78.65M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- TPST Stock
- Financials Tempest Therapeutics, Inc.